LYKALABS Stock Overview
Lyka Labs Limited, empresa farmacéutica, desarrolla, fabrica y comercializa formulaciones farmacéuticas e ingredientes farmacéuticos activos en diversos segmentos terapéuticos en la India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lyka Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹130.00 |
| 52 Week High | ₹144.30 |
| 52 Week Low | ₹88.50 |
| Beta | 1.15 |
| 1 Month Change | 8.83% |
| 3 Month Change | 3.38% |
| 1 Year Change | 20.20% |
| 3 Year Change | 392.42% |
| 5 Year Change | 329.04% |
| Change since IPO | 9.70% |
Recent News & Updates
Subdued Growth No Barrier To Lyka Labs Limited's (NSE:LYKALABS) Price
Jan 05
We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt
Nov 21Recent updates
Subdued Growth No Barrier To Lyka Labs Limited's (NSE:LYKALABS) Price
Jan 05We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt
Nov 21These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively
Jun 08A Look At The Fair Value Of Lyka Labs Limited (NSE:LYKALABS)
Mar 15Unpleasant Surprises Could Be In Store For Lyka Labs Limited's (NSE:LYKALABS) Shares
Aug 25Is Lyka Labs (NSE:LYKALABS) A Risky Investment?
Jun 11These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well
Feb 21Statutory Profit Doesn't Reflect How Good Lyka Labs' (NSE:LYKALABS) Earnings Are
Nov 05These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well
Nov 03Shareholder Returns
| LYKALABS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 15.5% | 0.006% | 1.9% |
| 1Y | 20.2% | 62.1% | 49.0% |
Rentabilidad frente al sector: LYKALABS obtuvo unos resultados inferiores a los del sector Indian Pharmaceuticals , que el año pasado arrojó un rendimiento del 65.6%.
Rentabilidad vs. Mercado: LYKALABS obtuvo unos resultados inferiores a los del mercado Indian, que fue del 45.9% el año pasado.
Price Volatility
| LYKALABS volatility | |
|---|---|
| LYKALABS Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: LYKALABS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LYKALABS (6%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 296 | Kunal Gandhi | https://www.lykalabs.com |
Lyka Labs Limited, una empresa farmacéutica, desarrolla, fabrica y comercializa formulaciones farmacéuticas e ingredientes farmacéuticos activos en varios segmentos terapéuticos en la India. La empresa fabrica y vende diversas formulaciones, como emoliente, esteroide tópico, agente antifúngico, antibacteriano tópico, tratamiento del acné, formulación dermatológica, analgésico, antienvejecimiento, loción limpiadora, cuidado del cabello, champú anticaspa, protector solar, antiacné, cosmecéutico, antioxidante, inhibidor de la bomba de protones, antipalúdico, antibacteriano, hormonas corticosteroides, cefalosporina, inyección de polvo seco, inhibidor de la resorción ósea, antioxidante/enfermedad hepática, antibiótico y productos liofilizados. También ofrece servicios de fabricación por contrato a varias grandes empresas farmacéuticas; y asistencia médica y técnica en las áreas de conocimientos técnicos de fabricación e instalaciones de fabricación, así como datos técnicos, como datos de pruebas de estabilidad de moléculas, perfil de impurezas y datos de estudios clínicos BA/BE.
Lyka Labs Limited Fundamentals Summary
| LYKALABS fundamental statistics | |
|---|---|
| Market cap | ₹4.30b |
| Earnings (TTM) | -₹36.68m |
| Revenue (TTM) | ₹1.02b |
4.2x
P/S Ratio-117.3x
P/E RatioIs LYKALABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYKALABS income statement (TTM) | |
|---|---|
| Revenue | ₹1.02b |
| Cost of Revenue | ₹425.24m |
| Gross Profit | ₹594.86m |
| Other Expenses | ₹631.54m |
| Earnings | -₹36.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 58.31% |
| Net Profit Margin | -3.60% |
| Debt/Equity Ratio | 79.2% |
How did LYKALABS perform over the long term?
See historical performance and comparison